ArticlePsychoneuroendocrinology2025
Characterizing longitudinal patterns of central and peripheral insulin resistance.
Article in Psychoneuroendocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Metabolic dysfunction of insulin resistance (IR) may compromise brain function decades before overt disease. We assessed biomarkers of peripheral and central IR for three years in 125 cognitively intact adults without diabetes or depression (23-61 y) to clarify their relative contributions to trajectories of metabolic and cognitive change. Peripheral IR was quantified by measuring steady-state plasma glucose (SSPG) concentration during the insulin-suppression test and ancillary metabolic indices; central IR was indexed by phosphorylated insulin-receptor-substrate-1 (p-IRS1) in neuron-derived extracellular vesicles (NDEs) isolated from plasma. Mixed-effects models controlling for age, sex and BMI showed that higher baseline SSPG concentration robustly predicted subsequent increases in HOMA-IR and fasting insulin but was unrelated to cognitive outcomes. In contrast, higher baseline NDE p-IRS1 predicted better global cognition (MMSE) over time, an effect strongest in younger participants, yet showed no association with peripheral metabolic change. Participants with concordantly low fasting insulin and C-peptide maintained roughly two-fold higher p-IRS1 than those in the highest tertiles, despite similar trajectories across visits. Neither peripheral nor central IR predicted telomere attrition. Cross-sectionally, p-IRS1 correlated inversely with SSPG concentration, BMI and leptin, suggesting compensatory brain-periphery coupling. These findings indicate that NDE-based markers capture a dimension of brain metabolic vulnerability distinct from classical peripheral measures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.